Device maker H&T Presspart has acquired the rights to market Biocorp’s Inspair inhaler sensor, the two companies have announced. The Inspair sensor, which fits onto standard metered dose inhalers, records inhaler usage data; provides audio and visual feedback on the patient’s inhalation technique; and can be reused for up to two years. H&T Presspart will continue to market its own smart device, the eMDI, which was launched in 2016; that device includes a sensor integrated directly into the inhaler.
Biocorp launched the Inspair sensor in 2016, and in 2018 the company announced that it had partnered with Lindal to commercialize Inspair in certain countries in South America, Southeast Asia, Eastern Europe, and the Middle East.
Biocorp CEO Eric Dessertenne commented, “We are very proud to entrust the distribution of Inspair to H&T Presspart, one of the world leaders in the respiratory disease market. This new major agreement further positions Biocorp as a provider of connected health solutions. After our success with Mallya, Biocorp now has a second solution with very high potential both in terms of business and the number of possible applications with Inspair.”
H&T Presspart President Christian Kraetzig said, “This strategic partnership underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialization of novel drug delivery solutions for patients.”
Read the H&T Presspart and Biocorp press release.
